Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

598.05 +9.78 (+1.66%)
Official Closing Price Updated: 7:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Weight-Loss Drugs Aren't To Blame For The Snack Pullback. Pepsi Offers This Reason.
Weight-loss drugs aren't the reason for suppressed shopping cart spending in a shaky economy, Pepsi executives say. 
Via Investor's Business Daily
Topics Economy
Exposures Economy
RayzeBio Is A New Contender in Radiopharmaceutical Arena, Will Attract Prominent Entities: JP Morgan
JP Morgan has initiated coverage on RayzeBio Inc (NASDAQ: RYZB), representing a pure-play opportunity in the radiopharmaceutical space. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisai Co Ltd (OTC: ESALY)/ Biogen Inc's (NASDAQ: 
Via Benzinga
Big Pharma’s Billion-Dollar Bets on Advanced Cancer Therapies
--News Direct-- 
Via News Direct
Exposures COVID-19
Peering Into Eli Lilly's Recent Short Interest
Via Benzinga
Looking At Eli Lilly's Recent Unusual Options Activity
Via Benzinga
Here's How Much $100 Invested In Eli Lilly 5 Years Ago Would Be Worth Today
Via Benzinga
Obesity Medication Insurance Coverage? Employers Embrace the Inclusion of Novo Nordisk's Wegovy in Health Coverage
Coverage for obesity medications, including Novo Nordisk A/S's (NYSE: NVO) Wegovy, is expected to expand among U.S. 
Via Benzinga
Why Eli Lilly Stock Crawled Higher Today
The pharmaceutical giant gets a lift from some good news on insurance coverage and a prognosticator's price-target lift. 
Via The Motley Fool
Jim Cramer's Take on Vertex: Tackling Opioid Addiction with New Drug in Pipeline
CNBC's Jim Cramer has drawn investors' attention to Vertex Pharmaceuticals (NASDAQ: VRTX), a biotechnology company currently in the late stages of developing a non-opioid drug to treat acute pain.  
Via Benzinga
Weight-Loss Drug Boom Has Another Ripple Effect - Rapid Growth Expected In Fill-Finish Market
Contract drug manufacturers are investing billions of dollars in expanding or constructing facilities that fill the injection pens used for weight-loss drugs like Novo Nordisk A/S's (NYSE: NVO)... 
Via Benzinga
This Dividend Stock Just Got Hit With a Short Report. Is Now a Buying Opportunity?
Coca-Cola is the latest subject of the Bear Cave, an online publisher of reports on stock to sell short. 
Via The Motley Fool
Check Out What Whales Are Doing With LLY
Via Benzinga
3 Biotech Stocks Ready to Break Out in 2024
These top three biotech companies are ready to roar into the new year with promising new trials, drugs, and innovative use of AI. 
Via InvestorPlace
3 No-Brainer Growth Stocks to Buy in October
The time is right to invest in these great stocks. 
Via The Motley Fool
Eli Lilly Stock, Novo Nordisk, Okta And UBS Among 21 New Names On IBD Stock Screens
Eli Lilly stock, Intuit, Futu, Global-e Online, DraftKings and Atlassian are among the 21 new stocks on IBD's proprietaray watchlists Friday. 
Via Investor's Business Daily
Shutdown Averted, Treasury Yields Flirt With 5%, Strong Payrolls Add to Fed Tightening Risk: The Week In The Markets
Catch up on the week's market highlights, from government funding drama to surging Treasury yields and an unexpectedly strong jobs report. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Snacks In The Ozempic Era: Food, Beverage Stocks Crash With Weight Loss Drugs On The Rise
Food and beverage stocks endure their toughest week since May 2022, driven by concerns over weight-loss drugs and shifting consumer behavior. 
Via Benzinga
Stock Market Ends On High Note Even As Yields Soar; Tesla In Focus: Weekly Review
A rally attempt continues amid soaring Treasury yields. 
Via Investor's Business Daily
Eli Lilly's Upcoming Obesity Drugs Highlight Bright Future, Says Optimistic Analyst
Shares of Eli Lilly And Co (NYSE: LLY) were climbing during Friday's trading session. The stock has been under pressure for the past three months, due to macro uncertainties and not fundamental... 
Via Benzinga
2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not
Eli Lilly's drug looks better on paper, but Ozempic was on the market first. 
Via The Motley Fool
Should You Sell This Stock After Another Regulatory Headwind?
This company has grabbed plenty of headlines this year, and they haven't all been good. 
Via The Motley Fool
Why Point BioPharma Global Stock Skyrocketed 86% This Week
Point Biopharma is being acquired by Eli Lilly. Here's what investors need to know. 
Via The Motley Fool
Thinking Of Buying Alexandria Real Estate Equities? Here Are The Properties And Tenants You'd Add To Your Portfolio
Via Benzinga
Biggest Oil Drop In A Year On Biden Security Plan, Magnificent 7 Stocks Do Not Like The New Data
To gain an edge, this is what you need to know today. 
Via Benzinga
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
This stock puts the "big" in big pharma after massive gains in recent years. 
Via The Motley Fool
Why Eli Lilly Stock Was Looking Sickly Today
Investors weren't necessarily satisfied with their company's latest asset buy. 
Via The Motley Fool
Crude Oil Moves Higher; POINT Biopharma Global Shares Jump
U.S. stocks extended losses toward the end of trading, with the S&P 500 falling around 1.5% on Tuesday. The Dow traded down 1.43% to 32,954.84 while the NASDAQ fell 1.98% to 13,044.24. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Eli Lilly Stock Is Trading Lower Today
Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday after the company announced the acquisition of POINT Biopharma for an aggregate purchase price 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.